| K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates J Straimer, NF Gnädig, B Witkowski, C Amaratunga, V Duru, ... Science 347 (6220), 428-431, 2015 | 825 | 2015 |
| A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms D Ménard, N Khim, J Beghain, AA Adegnika, M Shafiul-Alam, O Amodu, ... New England Journal of Medicine 374 (25), 2453-2464, 2016 | 592 | 2016 |
| Artemisinin action and resistance in Plasmodium falciparum L Tilley, J Straimer, NF Gnädig, SA Ralph, DA Fidock Trends in parasitology 32 (9), 682-696, 2016 | 419 | 2016 |
| Targeting the Cell Stress Response of Plasmodium falciparum to Overcome Artemisinin Resistance C Dogovski, SC Xie, G Burgio, J Bridgford, S Mok, JM McCaw, ... PLoS biology 13 (4), e1002132, 2015 | 367 | 2015 |
| Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies MI Veiga, SK Dhingra, PP Henrich, J Straimer, N Gnädig, AC Uhlemann, ... Nature communications 7 (1), 11553, 2016 | 308 | 2016 |
| Site-specific genome editing in Plasmodium falciparum using engineered zinc-finger nucleases J Straimer, MCS Lee, AH Lee, B Zeitler, AE Williams, JR Pearl, L Zhang, ... Nature methods 9 (10), 993-998, 2012 | 210 | 2012 |
| Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness BH Stokes, SK Dhingra, K Rubiano, S Mok, J Straimer, NF Gnädig, I Deni, ... Elife 10, e66277, 2021 | 148 | 2021 |
| Plasmodium falciparum K13 Mutations Differentially Impact Ozonide Susceptibility and Parasite Fitness In Vitro J Straimer, NF Gnädig, BH Stokes, M Ehrenberger, AA Crane, DA Fidock MBio 8 (2), 10.1128/mbio. 00172-17, 2017 | 128 | 2017 |
| High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine J Straimer, P Gandhi, KC Renner, EK Schmitt The Journal of infectious diseases 225 (8), 1411-1414, 2022 | 94 | 2022 |
| Genome-wide screen identifies new candidate genes associated with artemisinin susceptibility in Plasmodium falciparum in Kenya S Borrmann, J Straimer, L Mwai, A Abdi, A Rippert, J Okombo, S Muriithi, ... Scientific reports 3 (1), 3318, 2013 | 88 | 2013 |
| Insights into the intracellular localization, protein associations and artemisinin resistance properties of Plasmodium falciparum K13 NF Gnädig, BH Stokes, RL Edwards, GF Kalantarov, KC Heimsch, ... PLoS pathogens 16 (4), e1008482, 2020 | 84 | 2020 |
| Balancing drug resistance and growth rates via compensatory mutations in the Plasmodium falciparum chloroquine resistance transporter I Petersen, SJ Gabryszewski, GL Johnston, SK Dhingra, A Ecker, ... Molecular microbiology 97 (2), 381-395, 2015 | 75 | 2015 |
| A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance PM O’Neill, RK Amewu, SA Charman, S Sabbani, NF Gnädig, J Straimer, ... Nature Communications 8 (1), 15159, 2017 | 74 | 2017 |
| Efficacy of cipargamin (KAE609) in a randomized, Phase II dose-escalation study in adults in sub-Saharan Africa with uncomplicated Plasmodium falciparum malaria EK Schmitt, G Ndayisaba, A Yeka, KP Asante, MP Grobusch, E Karita, ... Clinical Infectious Diseases 74 (10), 1831-1839, 2022 | 70 | 2022 |
| Artemisinin resistance phenotypes and K13 inheritance in a Plasmodium falciparum cross and Aotus model JM Sá, SR Kaslow, MA Krause, VA Melendez-Muniz, RE Salzman, ... Proceedings of the National Academy of Sciences 115 (49), 12513-12518, 2018 | 58 | 2018 |
| Characterization of novel antimalarial compound ACT-451840: preclinical assessment of activity and dose–efficacy modeling A Le Bihan, R de Kanter, I Angulo-Barturen, C Binkert, C Boss, R Brun, ... PLoS medicine 13 (10), e1002138, 2016 | 49 | 2016 |
| A G358S mutation in the Plasmodium falciparum Na+ pump PfATP4 confers clinically-relevant resistance to cipargamin D Qiu, JV Pei, JEO Rosling, V Thathy, D Li, Y Xue, JD Tanner, ... Nature communications 13 (1), 5746, 2022 | 40 | 2022 |
| Editing the Plasmodium vivax Genome, Using Zinc-Finger Nucleases RR Moraes Barros, J Straimer, JM Sa, RE Salzman, VA Melendez-Muniz, ... The Journal of Infectious Diseases 211 (1), 125-129, 2015 | 39 | 2015 |
| The Plasmodium PI(4)K inhibitor KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites L Dembele, X Ang, M Chavchich, GMC Bonamy, JJ Selva, MYX Lim, ... Scientific reports 7 (1), 2325, 2017 | 35 | 2017 |
| Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies. Nat Commun 7: 11553 MI Veiga, SK Dhingra, PP Henrich, J Straimer, N Gnädig, AC Uhlemann, ... | 31 | 2016 |
